Literature DB >> 23240642

Editors' pick 2012.

Lionel D Lewis, Andrew Somogyi, Yoon K Loke, Albert Ferro, Adam F Cohen, James M Ritter.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23240642      PMCID： PMC3555040          DOI： 10.1111/bcp.12030

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  26 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging.

Authors:  Ying J Cao; Brian S Caffo; Edward J Fuchs; Linda A Lee; Yong Du; Liye Li; Rahul P Bakshi; Katarzyna Macura; Wasif A Khan; Richard L Wahl; Lisa A Grohskopf; Craig W Hendrix
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Medication errors.

Authors:  Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

4.  Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

Authors:  Paul K L Chin; Jane W A Vella-Brincat; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

5.  The science of prescribing.

Authors:  Derek G Waller
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

6.  Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

Authors:  Anne-Joy M de Graan; Cynthia S Lancaster; Amanda Obaidat; Bruno Hagenbuch; Laure Elens; Lena E Friberg; Peter de Bruijn; Shuiying Hu; Alice A Gibson; Gitte H Bruun; Thomas J Corydon; Torben S Mikkelsen; Aisha L Walker; Guoqing Du; Walter J Loos; Ron H N van Schaik; Sharyn D Baker; Ron H J Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

7.  RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.

Authors:  P Therasse; A Le Cesne; M Van Glabbeke; J Verweij; I Judson
Journal:  Eur J Cancer       Date:  2005-07       Impact factor: 9.162

8.  Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children.

Authors:  Massimo Cella; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

10.  The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

Authors:  Lionel D Lewis; Antonius A Miller; Kouros Owzar; Robert R Bies; Svetlana Markova; Chen Jiang; Deanna L Kroetz; Merrill J Egorin; Howard L McLeod; Mark J Ratain
Journal:  Pharmacogenet Genomics       Date:  2013-01       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.